gsk2330811
mAbexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 21, 2015 (NCT02386436)
Timeline
Indications
Mechanism of action
- Oncostatin-MINHIBITOR
OSM inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- gsk2330811
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04151225 | Phase 2 | Mar 3, 2020 | GlaxoSmithKline |
| NCT04138043 | Phase 1 | Nov 26, 2019 | GlaxoSmithKline |
| NCT03041025 | Phase 2 | Jun 5, 2017 | GlaxoSmithKline |
| NCT02386436 | Phase 1 | Apr 21, 2015 | GlaxoSmithKline |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 4 | 4 | 2 | 2015 |
1 organizations
Page 1 / 1